Vobatensine E






Names

    • Vobatensine E

Attributes

  • Canonical SMILES

    C/C=C7\C1CC(C2=C(OC)C=CC3=C2NC4=C3CCN5C[C@@H]6CC4C5C(CC)C6)C9=C(C8=CC=CC=C8N9)CC(N(C7)C)[C@H]1[C@](OC)=O

  • InChI

    InChI=1S/C41H50N4O3/c1-6-23-16-22-17-31-37-27(14-15-45(20-22)40(23)31)26-12-13-34(47-4)36(39(26)43-37)30-18-28-24(7-2)21-44(3)33(35(28)41(46)48-5)19-29-25-10-8-9-11-32(25)42-38(29)30/h7-13,22-23,28,30-31,33,35,40,42-43H,6,14-21H2,1-5H3/b24-7-/t22-,23?,28?,30?,31?,33?,35-,40?/m0/s1

  • Molecule Class: Alkaloids
  • TPSA: 73.59
  • #RotBonds: 4
  • MW: 646.8760000000001
  • HBD: 2
  • HBA: 5
  • logP: 7.161700000000009
  • Chemical Formula: C41H50N4O3


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. corymbosa Malaysia, China 1679252 GK604

External Databases


References

  • Vobatensines A-F, Cytotoxic Iboga-Vobasine Bisindoles from Tabernaemontana corymbosa. J Nat Prod, 2016 (PMID 26918761).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Growth inhibitory

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -5.93
    Human Oral Bioavailability 20% Non-Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -1.58
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability 535.31
    Distribution Blood-Brain Barrier (Central Nervous System) -3.08
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 1.5
    Plasma Protein Binding 64.97
    Steady State Volume of Distribution 5.23
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Substrate
    CYP 3A4 Inhibitor Non-Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Inhibitor
    Excretion Clearance 12.1
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Safe
    Bee Toxic
    Bioconcentration Factor -10.14
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -1.2
    Liver Injury II Safe
    hERG Blockers Toxic
    Daphnia Maga 7.89
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Safe
    T. Pyriformis -969662.21
    Rat (Acute) 2.92
    Rat (Chronic Oral) 2.31
    Fathead Minnow 1227.26
    Respiratory Disease Toxic
    Skin Sensitisation Safe
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 105830.56
    Hydration Free Energy -2.92
    Log(D) at pH=7.4 5.65
    Log(P) 6.52
    Log S -5.77
    Log(Vapor Pressure) -3452.81
    Melting Point 263.62
    pKa Acid 0.08
    pKa Basic 6.95